Amring Pharmaceuticals Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Amring Pharmaceuticals

Access the complete profile.

Amring Pharmaceuticals Fast Facts

Revenue	$10 - $100 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing
Address	1205 Westlakes Dr Suite 275 Berwyn, PA 19312

Note: Revenues for privately held companies are statistical evaluations.


Amring Pharmaceuticals's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Amring Pharmaceuticals's annual revenues are $10 - $100 million (see exact revenue data)
• What industry is the company in?
  • Amring Pharmaceuticals is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Amring Pharmaceuticals Annual Revenue and Growth Rate

Amring Pharmaceuticals	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$10 - $100 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Amring Pharmaceuticals's revenues are gauged from an analysis of company filings.

Amring Pharmaceuticals's Income Statement (based on Industry Averages)

Amring Pharmaceuticals P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Amring Pharmaceuticals is developing and marketing. Amring Pharmaceuticals doesn't have any recent trademark applications, indicating Amring Pharmaceuticals is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
A Pharmaceutical preparations for use in the treatment of urinary, blood, and bowel disorders and diseases; muscle relaxants	04/11/2019
AMGLIDIA Pharmaceutical preparations for treating neonatal diabetes and premature hyperglycemia	06/30/2017
AMRING Pharmaceutical products and substances for use in the prevention and treatment of urinary, blood, and dermal disorders and diseases	06/01/2017

See all trademarks and details in the Full Report.

Market Share of Amring Pharmaceuticals's Largest Competitors

A competitive analysis shows these companies are in the same general field as Amring Pharmaceuticals, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Amring Pharmaceuticals. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
FUJIREBIO DIAGNOSTICS	Malvern, PA	100
FLAMMA USA	Malvern, PA	6
SHIRE HOLDINGS US AG	Exton, PA	6
AMRING PHARMACEUTICALS	Berwyn, PA	4
VERRICA PHARMACEUTICALS	West Chester, PA	4
ITF PHARMA	Berwyn, PA	2

Future Competition: Amring Pharmaceuticals's Fastest Growing Competitors

These companies are in the same general field as Amring Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)